Minocycline
- Generic Name
- Minocycline
- Brand Names
- Amzeeq, Arestin, Dynacin, Minocin, Minolira, Solodyn, Ximino, Zilxi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27N3O7
- CAS Number
- 10118-90-8
- Unique Ingredient Identifier
- FYY3R43WGO
- Background
Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetracyclines.
...
- Indication
Oral and topical minocycline are indicated to treat inflammatory lesions of acne vulgaris. Subgingival microspheres are indicated as an adjunct treatment in the reduction of pocket depth in adults with periodontitis. Oral and intravenous formulations are indicated to treat infections of susceptible microorganisms. These include rickettsiae, Mycoplasma pneumo...
- Associated Conditions
- Bartonellosis, Brucellosis, Campylobacter fetus, Chancroid, Cholera (Disorder), Conjunctivitis, Inclusion, Granuloma Inguinale, Lymphogranuloma Venereum, Nongonococcal urethritis, Periodontitis, Plague, Psittacosis, Q Fever, Relapsing Fever, Respiratory Tract Infections (RTI), Rickettsia Infections, Rickettsialpox, Rocky Mountain Spotted Fever, Trachoma, Tularemia, Typhus infections, Inflammatory lesions
- Associated Therapies
- -
National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Neuroprotection Trial
- Conditions
- First Posted Date
- 2003-06-25
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 195
- Registration Number
- NCT00063193
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
Minocycline to Treat Amyotrophic Lateral Sclerosis
- Conditions
- First Posted Date
- 2002-10-17
- Last Posted Date
- 2007-12-21
- Target Recruit Count
- 400
- Registration Number
- NCT00047723
- Locations
- 🇺🇸
Drexel University College of Medicine, Hahnemann Campus, Philadelphia, Pennsylvania, United States
🇺🇸University of Vermont, Burlington, Vermont, United States
🇺🇸Methodist Hospital, Houston, Texas, United States
Minocycline in Patients With Huntington's Disease
- Conditions
- First Posted Date
- 2002-01-25
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- FDA Office of Orphan Products Development
- Target Recruit Count
- 63
- Registration Number
- NCT00029874
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.